These latter include antibodies to the nuclear pore complex (NPC) that target gp210 (a glycoprotein of the nuclear pore complex) and nucleoporin p62, as well as antibodies to multiple nuclear dots that target Sp100 (a nuclear body speckled 100KDa protein) and PML (promyelocytic leukemia protein), which are found in about 50% of patients with PBC [5]. This evidence concerns the gene PML and primary biliary cholangitis.